HARP News and Press, Harpoon Therapeutics Inc. From 04/27/20

SOUTH SAN FRANCISCO, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that the first patient has been dosed with HPN217 in a Phase 1/2 clinical trial focu...

Amid widespread uncertainty in healthcare around COVID-19 impact, Baird is focusing on clinical catalysts that continue to power biotech picks - and in particular it's declaring fresh picks on two stocks with data forthcoming. More news on: Constellation Pharmaceuticals, Inc., Blueprint Me...

Andrew R. Robbins, former Chief Operating Officer, Array Biopharma Dr. Joseph S. Bailes, former President of American Society of Clinical Oncology (ASCO) SOUTH SAN FRANCISCO, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immuno...

A string of scientific breakthroughs in recent years has made oncology the most-watched corner of the biopharmaceutical industry, and many of those breakthroughs were first presented at the American Society of Clinical Oncology's (ASCO) annual meeting. However, gathering scientists from all ove...

The following medical companies have filed for mixed shelf offerings: More news on: iBio, Inc., Verrica Pharmaceuticals Inc., Inovio Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...

The following slide deck was published by Harpoon Therapeutics, Inc. in conjunction with their 2019 Q4 earnings Read more ...

Harpoon Therapeutics, Inc. (HARP) Q4 2019 Earnings Conference Call March 12, 2020, 04:30 PM ET Company Participants Robert Uhl - MD, Westwicke, IR Gerald McMahon - President and CEO Georgia Erbez - CFO Conference Call Participants David Ruch - SVB Leerink Michael Ulz - Ba...

Harpoon Therapeutics (NASDAQ: HARP ): Q4 GAAP EPS of -$0.58 misses by $0.06 . More news on: Harpoon Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Exclusive worldwide option and license transaction for HPN217 with AbbVie and expansion of existing discovery collaboration in November 2019 could provide up to $100 million in upfront/near-term milestones and up to $2.3 billion in future payments     HPN424 interim Phase 1 d...

Insider buying decreased significantly last week with insiders purchasing $11.65 million of stock compared to $48.31 million in the week prior. Selling also decreased with insiders selling $569.34 million of stock last week compared to $714.05 million in the week prior. Sell/Buy Ratio: The...